Objectives: The aim of the study was to estimate the risk of high-grade cervical and vaginal intraepithelial neoplasia (CIN/VAIN 2+) and cancer among women treated surgically for high-grade vulvar intraepithelial neoplasia (HGVIN) and vulvar cancer.
1
Because patients infected with HPV can have multifocal disease, regular examination of the lower genital tract is recommended for women treated for VIN and vulvar cancer. 2, 3 Current guidelines set forth by the American College of Obstetricians and Gynecologists and the American Society for Colposcopy and Cervical Pathology (ASCCP) state that women with VIN who have had a complete response to initial treatment, and no new lesions at their 6-and 12-month follow-up visits should be monitored by visual inspection of the vulva annually thereafter. 4 Recurrence rates after treatment for VIN range from 9% to 50% and are associated with cigarette smoking, larger lesions, and positive excision margins. 2, 3, [5] [6] [7] As an adjunct to vulvar surveillance examination, cervical/vaginal cytologic screening is recommended on the basis of expert opinion only. According to the National Comprehensive Cancer Network 2017 guidelines, 8 cervical/vaginal cytology screening can be considered for detection of lower genital tract dysplasia, although its value in detection of recurrent genital tract cancer is considered limited. Subsequent risks of cervical or vaginal intraepithelial neoplasia (CIN or VAIN) and cancer after treatment for HGVIN/vulvar cancer are not well defined. This is especially true for women who have previously undergone hysterectomy because risk for VAIN is low. Previous work is dated, includes low-grade cervical disease now understood to represent non-neoplastic HPV infection, and may involve case selection that biases risk estimates. Nonetheless, extant studies show substantial variation in risk, between 8% and 85%, of coexisting cervical disease at time of diagnosis of vulvar HSIL or cancer. [9] [10] [11] We were unable to identify studies quantifying the subsequent risks of cervical or vaginal disease after vulvar disease treatment. Therefore, our study objectives were to estimate the risk of cervical or VAIN or cancer after surgical treatment for HGVIN/vulvar cancer with the goal of providing evidence-based recommendations for cytologic screening of these women. We hypothesized that among women treated surgically for HGVIN/vulvar cancer, with and without previous hysterectomy, the subsequent risk for CIN/VAIN 2+ and cervical/ vaginal cancer is less than 1% and 3%, respectively. We also hypothesized that 75% of abnormal cytology obtained after vulvar surgery for HGVIN/vulvar cancer do not lead to high-grade CIN/ VAIN or cervical/vaginal cancer.
MATERIALS AND METHODS
This was a retrospective cohort study evaluating all patients surgically treated for VIN and vulvar cancer by the Division of Gynecologic Oncology at Washington University School of Medicine from January 1, 2006, to December 31, 2010. Before initiation of our study, all procedures were reviewed and approved by Washington University's Human Research Protection Office (institutional review board project number 201503040). Abstracted data from patient medical records were deidentified, and because of the retrospective nature of this project, informed consent was waived.
Eligible women were older than 18 years with a histologically confirmed diagnosis of HGVIN or vulvar cancer. Patients were included if they had at least one liquid-based cytology after vulvar surgery. Decisions on cervical/vaginal cancer screening and management after abnormal cytology, including colposcopy, were at the discretion of the treating gynecologic oncologist. All specimens underwent centralized review by subspecialized gynecologic pathologists in the Ackerman Laboratory of Surgical Pathology, Barnes-Jewish Hospital/Washington University School of Medicine. Women were excluded if they had no follow-up after their vulvar surgery or never underwent surveillance cervical/ vaginal cytology. Women were also ineligible if they underwent a vulvar excision procedure for low-grade squamous intraepithelial lesion (LSIL) of the vulva or were treated with laser ablation. All cases of vulvar melanoma in situ, invasive melanoma, or Paget disease were excluded.
Cytology results were read according to the Bethesda system for cervicovaginal cytologic diagnosis as normal, atypical squamous cells of uncertain significance (ASC-US), ASC-US with high-risk HPV positivity (ASC-US + HPV), atypical squamous cells, cannot exclude high-grade intraepithelial lesions (ASC-H), LSIL, high-grade squamous intraepithelial lesions (HSIL), and atypical glandular cells (AGC) favor neoplasia. 12 Demographic and clinical characteristics were summarized by descriptive statistics, i.e., mean and SD for continuous variables, and count and percentage for categorical variables. The group difference between normal and abnormal cytology cases after vulvar therapy was examined by independent t test for continuous variables and Fisher exact or tests for categorical variables, depending on the distribution of each individual variable. All the tests were two-sided, and the significance level was set at 0.05. The uncertainty of estimates was assessed by confidence intervals. To test our hypotheses, the one-sample binominal proportion test was used to assess whether a sample proportion was significantly different from our hypothesized value. We used a composite outcome for a high-grade cervical/vaginal disease based on the 
RESULTS
We reviewed 234 charts of women undergoing vulvar surgery between 2006 and 2010, of which 43 were excluded because of no cervical/vaginal surveillance cytology after vulvar surgery. Our final analysis included 191 women who contributed 816 cytology results. The median number of surveillance cytology results after vulvar surgery per patient was two (range = 1-18). Most women were white (84%) with a mean age of 52.6 years at the time of diagnosis. Primary vulvar lesions included VIN 2 (n = 10, 5%), VIN 3 (n = 102, 53%), and carcinoma (n = 79, 41%). Risk factors for abnormal cytology after vulvar surgical management included white race (p = .002), HIV (p = .021), other immunosuppression (p = .007), and previous abnormal cervical/ vaginal cytology (p = .008) (see Table 1 ).
Over a median surveillance interval of 3.7 years, 71 (37%) women treated for HGVIN/vulvar cancer had abnormal cervical/ vaginal cytology, including 47 (25%) low-grade (ASCUS and LSIL), 23 (12%) high-grade (ASC-H, HSIL, AGC), and 1 (0.5%) carcinoma (see Table 2 ). This led to 44 (62%, 44/71) cervicovaginal colposcopic evaluations with biopsies resulting in 30 (42%, 30/71) histologic diagnoses of normal or CIN 1/VIN 1, which was less than our hypothesized rate of 75% (p = 1). Among the 44 women with cervicovaginal colposcopic evaluation, 5 were diagnosed with CIN/VAIN 2 and 9 CIN/VAIN 3, but overall, this represented 7% of our total sample population of 191 women. Subgroup analysis by previous hysterectomy status also resulted in higher than expected risk for CIN 2+/VAIN 2+. Among women treated for HGVIN/ vulvar cancer without previous hysterectomy (n = 124), the subsequent risk for high-grade cervical/vaginal disease or cancer (n = 10, 8%) was greater than our hypothesized rate of 3% (p < .001). Furthermore, among women who had a hysterectomy (n = 57) before vulvar surgery, the subsequent risk for high-grade VAIN/vaginal cancer (n = 6, 11%) was also greater than our hypothesized rate of 1% (p < .0001). Overall, there was no significant difference in high-grade cervical/vaginal disease after vulvar surgery between women with and without a hysterectomy (11%, CIN 2+ vs 8%, VAIN 2+, p = .59).
The one patient with malignant cytology was an 82 year old with stage III squamous cell carcinoma of the vulva who had undergone a radical vulvectomy with advancement flaps and bilateral inguinal lymph node dissection followed by adjuvant pelvic radiation. She underwent a total of seven surveillance cervical cytologies at 6-month intervals, 6 that were negative and 1 LSIL (19 months after surgery). She was lost to follow-up for 40 months, but then presented to an emergency department with heavy postmenopausal bleeding nearly 8 years after her vulvar surgery. Her work-up included cervical cytology and dilation and curettage, which both confirmed a grade 1 endometrioid adenocarcinoma.
Univariate analysis demonstrated that nonwhite race (odds ratio [OR] = 3.3, 95% CI = 1.50-7.36), immunosuppression (OR = 4.19, 95% CI = 1.76-9.94), and previous abnormal cytology (OR = 2.7, 95% CI = 1.29-5.78) were associated with abnormal high-grade cytology (see Table 3 ). In our multivariate logistic regression model, after adjusting for age, race, smoking status, previous abnormal cytology, and previous hysterectomy, immunosuppression remained significantly associated with the development of abnormal cytology after vulvar 
DISCUSSION
Women with HGVIN/vulvar cancer are at risk for coexisting cervical or vaginal disease and should be screened with cervical/ vaginal cytology before treatment for HGVIN/vulvar cancer. Those treated surgically for HGVIN/vulvar cancer have an 8% to 11% risk of high-grade cervical/vaginal cytology depending on previous hysterectomy status and an overall 5% risk of CIN 3+. Immunosuppression, defined as HIV seropositive or a transplant patient on immunosuppressive medications, remained a statistically significant risk factor for high-grade cytology even after adjusting for potential confounders. To put our study results in clinical context, we apply the concept of "similar management for similar risk" per the 2012 ASCCP guidelines. 13 According to their criteria, a 6-to 12-month return for a 5-year CIN 3+ risk of 2% to 5%, and a 3-year return for risk of 0.1% to 2% are recommended. Extrapolating these standards to women surgically treated for HGVIN/vulvar cancer, especially in the initial years after treatment, they should be followed with at least annual cytology testing. Expeditious follow-up of abnormal results should be in accordance with ASCCP guidelines. Even our most conservative calculation of CIN 3+ risk that includes all 234 patients, assuming those with no surveillance cytology (n = 43) would have had a negative result, equals 3.8%. Furthermore, if we then excluded all immunocompromised patients (n = 30), including the three who had CIN 3, the risk decreases from 3.8% (9/234) to 2.9% (6/204), which is still within the threshold set forth by the ASCCP to recommend a short interval surveillance. Therefore, taking into consideration our small sample size and a conservative estimate, we recommend all women with HGVIN/cancer should have cervical/vaginal cytology before therapy. Women with a negative result should be followed with cytology testing at 1-to 3-year intervals, and those with an abnormal result should have colposcopy and managed according to ASCCP guidelines.
Vulvar intraepithelial neoplasias and vulvar cancers are commonly caused by carcinogenic types of HPV, which also can cause similar vaginal and cervical lesions.
14 Cervical disease risk is increasing among women with genital warts and those infected with HIV; however, the subsequent risk of CIN and VAIN and cancer is not well defined. Previous work is dated, and the estimated risk of coexisting cervical/vaginal disease at the time of HGVIN/vulvar cancer, although quite substantial, varies between 8% and 85% because of biases of case selection and inclusion of low-grade cervical disease. 9-11 Mitchell et al. 11 found cervical lesions in 17 (10%) of 169 women with VIN or vulvar cancer. Spitzer et al. 15 found cervical disease of various grades in 164 (85%) of 194 women with vulvar lesions, although many were condylomas. Lastly, Basta et al. 9 found CIN or cervical/vaginal cancer in 14 (8%) of 68 women with coexisting VIN or vulvar cancer.
A study by Hording et al. 10 provided HPV genotype data to support the concept that VIN 3 and some vulvar carcinomas are highly associated with other genital primary tumor(s) due to a "field effect" of an underlying HPV infection involving the entire lower genital tract. They examined cervical and vulvar tissues from 143 women with multifocal genital neoplasia for HPV types 6, 11, 16, 18, and 33. For a 5-year median follow-up, they found CIN 3 or cervical cancer in 39 (27%) women with vulvar cancer or VIN 3. Human papillomavirus deoxyribonucleic acid testing revealed that 81% of patients with double primary tumors had the same HPV type in both lesions. However, one of the major limitations of their study is lack of data from seropositive HIV women or those receiving immunosuppressive therapy. Although our retrospective study did not include routine HPV testing, our results corroborate with their increased rates of CIN/VAIN 2+ in women with HGVIN/vulvar carcinoma. Our study further strengthens generalizability of results, given that we also included immunocompromised patients, although we acknowledge the small percentage of HIVseropositive women.
Given our small sample size of immunocompromised women, we cannot reliably predict the prevalence of abnormal cytology after surgical treatment for HGVIN/vulvar cancer. However, immunocompromised women are at substantial risk for CIN 3+ regardless of vulvar disease history. Specifically, HIV-seropositive women are at greater risk for abnormal cytology results than seronegative women and their results are more often high grade. 16, 17 The Women's Interagency HIV Study recently published on the longterm cumulative incidence of CIN 3+ after abnormal cytology and showed that less than 40% of HIV-seropositive women with ASCUS and LSIL developed CIN 2+ for 10 years and less than 20% developed CIN 3+. Although our study had a shorter follow-up period, our results corroborate with their findings that HIV infection is a risk factor for CIN 2+. Interestingly, they also showed that it was not a significant risk factor for CIN 3+, suggesting that HIV infection may disproportionately increase CIN 2. Findings from our multivariate analysis highlight the correlation between immunosuppression and abnormal cytology, lending further support that HIV seropositive women with abnormal cytology merit scrupulous surveillance. 4, 18 Some limitations of our study are inherent to our retrospective study design, such as lack of randomization, limited sample size, and incomplete follow-up. However, sociodemographic and clinical characteristics displayed in Table 1 show that our two treatment groups were overall well-balanced. We also addressed the possibility of selection bias by comparing baseline characteristics between women who were excluded and included on the basis of availability of follow-up data, and no statistically significant differences were detected. In addition, surveillance of cervical/ vaginal cytology for women with HGVIN/vulvar cancer was at the discretion of the gynecologic oncology provider, because our practice has not yet adopted a standardized protocol for these particular patients. With regard to our sample size, we were limited by the prevalence of high-grade preinvasive and invasive vulvar disease, but relied on our large, university-based clinical practice, and included all patients who met eligibility criteria with follow-up of at least one cervical/vaginal cytology result. Furthermore, our retrospective chart review was limited by the original documentation of the pathology reports, which did not include subclassification of VIN according to the International Society for the Study of Vulvovaginal Disease as either usual type or differentiated. 19 Nonetheless, we acknowledge the differences in morphology and behavior of these two precursors and recommend that future studies report VIN in accordance with the International Society for the Study of Vulvovaginal Disease classification to enhance diagnostic reproducibility but also to further individualize the risk of a field effect of an underlying HPV infection involving the entire lower genital tract.
Currently, we are expanding our study methods to include retrospective data from three other academic centers across the country to more accurately estimate the incidence of CIN/VAIN 2+, CIN/VAIN 3+, and cervical/vaginal cancer among women treated surgically for HGVIN/vulvar cancer. In addition to validating our study results with this larger cohort, we aim to explore the risk among women with an initial negative cytology screening result after vulvar treatment and assess whether this negative cytology result portends a low enough subsequent risk of CIN/ VAIN 2+ to allow for longer screening intervals. Other areas for future research include evaluation of CIN/VAIN 2+ prevalence among women with HGVIN treated with laser or imiquimod compared with surgical management. A much broader question that remains to be addressed is the role for cotesting in a population that is likely to have a high prevalence of high-risk HPV.
CONCLUSIONS
Women treated surgically for HGVIN/vulvar cancer are at substantial risk for having an abnormal cytology. During surveillance screening, the prevalence of VAIN 2+ was 11% in women with a previous hysterectomy and 8% for CIN 2+ in women with an intact cervix. Extrapolating from guidelines set forth by the ASCCP, our findings suggest that women who undergo surgical treatment for HGVIN/vulvar cancer, especially those who are immunosuppressed, should be followed with at least annual cervical/vaginal cytology during the first several years after vulvar treatment. Those with an abnormal result should have colposcopy and should be followed according to ASCCP guidelines.
